|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6281015B1
(en)
|
1994-12-16 |
2001-08-28 |
Children's Medical Center Corp. |
Localized delivery of factors enhancing survival of transplanted cells
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
|
US6273913B1
(en)
*
|
1997-04-18 |
2001-08-14 |
Cordis Corporation |
Modified stent useful for delivery of drugs along stent strut
|
|
US8790391B2
(en)
|
1997-04-18 |
2014-07-29 |
Cordis Corporation |
Methods and devices for delivering therapeutic agents to target vessels
|
|
US6984635B1
(en)
*
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
EP1319008B1
(en)
*
|
2000-09-19 |
2008-10-15 |
Wyeth |
Water soluble rapamycin esters
|
|
US6399625B1
(en)
*
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
|
US20070276473A1
(en)
*
|
2000-09-29 |
2007-11-29 |
Llanos Gerard H |
Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
|
|
US20060222756A1
(en)
*
|
2000-09-29 |
2006-10-05 |
Cordis Corporation |
Medical devices, drug coatings and methods of maintaining the drug coatings thereon
|
|
AU9486901A
(en)
|
2000-09-29 |
2002-04-08 |
Cordis Corp |
Coated medical devices
|
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
IL155952A0
(en)
*
|
2000-11-28 |
2003-12-23 |
Wyeth Corp |
Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
PL409579A1
(pl)
|
2001-02-19 |
2015-03-02 |
Novartis Ag |
Leczenie raka
|
|
EP1385551B1
(en)
*
|
2001-04-06 |
2008-09-03 |
Wyeth |
Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
|
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
ZA200603888B
(en)
*
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
BR0211986A
(pt)
|
2001-08-22 |
2004-09-28 |
Wyeth Corp |
29-enóis de rapamicina
|
|
MXPA04001523A
(es)
*
|
2001-08-22 |
2004-05-31 |
Wyeth Corp |
Dialdehidos de rapamicina.
|
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
BR0306811A
(pt)
*
|
2002-01-11 |
2004-10-26 |
Sankyo Co |
Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
PL215263B1
(pl)
*
|
2002-02-25 |
2013-11-29 |
Elan Pharm Inc |
Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
|
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
|
US7217796B2
(en)
*
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
|
EP1511473B8
(en)
|
2002-05-27 |
2013-07-24 |
Novartis AG |
Bis-aromatic alkanols
|
|
AU2003247483A1
(en)
*
|
2002-05-30 |
2003-12-31 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
|
CA2492153C
(en)
|
2002-07-16 |
2012-05-08 |
Biotica Technology Limited |
Production of polyketide fkbp-ligand analogues
|
|
NZ537829A
(en)
|
2002-07-30 |
2006-09-29 |
Wyeth Corp |
Parenteral formulations containing a rapamycin hydroxyester
|
|
EP1546369A4
(en)
*
|
2002-08-12 |
2007-01-17 |
Univ Michigan |
DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
|
|
DE60324609D1
(de)
*
|
2002-09-17 |
2008-12-18 |
Wyeth Corp |
GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
|
|
EP1539270A1
(en)
*
|
2002-09-18 |
2005-06-15 |
Medtronic Vascular, Inc. |
Controllable drug releasing gradient coatings for medical devices
|
|
KR20080103117A
(ko)
|
2002-09-24 |
2008-11-26 |
노파르티스 아게 |
탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
|
|
WO2004060283A2
(en)
|
2002-12-16 |
2004-07-22 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
|
DK1592457T3
(da)
*
|
2003-01-27 |
2012-10-22 |
Endocyte Inc |
Folat-vinblastin-konjugat som lægemiddel
|
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
|
UA83484C2
(uk)
*
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
ATE352301T1
(de)
*
|
2003-04-22 |
2007-02-15 |
Wyeth Corp |
Antineoplastische zusammensetzungen
|
|
BRPI0409681A
(pt)
*
|
2003-04-23 |
2006-04-18 |
Wyeth Corp |
derivados de wortmanina solúveis em água
|
|
US7160867B2
(en)
*
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
|
BRPI0410439A
(pt)
|
2003-05-19 |
2006-06-06 |
Irm Llc |
compostos e composições imunossupressoras
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
TW200500065A
(en)
*
|
2003-05-21 |
2005-01-01 |
Wyeth Corp |
Antiarthritic combinations
|
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
|
WO2005017149A1
(en)
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
|
WO2005010010A1
(en)
*
|
2003-07-16 |
2005-02-03 |
Wyeth |
Cci-779 isomer c
|
|
CN1829514A
(zh)
*
|
2003-07-25 |
2006-09-06 |
惠氏公司 |
Cci-779冻干制剂
|
|
KR20060057605A
(ko)
*
|
2003-08-07 |
2006-05-26 |
와이어쓰 |
Cci-779의 위치선택적 합성 방법
|
|
RU2345999C2
(ru)
*
|
2003-09-03 |
2009-02-10 |
Уайт |
Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
|
|
AR046194A1
(es)
*
|
2003-11-04 |
2005-11-30 |
Mayo Foundation |
Metodo de tratamiento del linfoma de celulas del manto
|
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
JP2007517879A
(ja)
*
|
2004-01-08 |
2007-07-05 |
ワイス |
Cci−779経口投与用の直接圧縮可能な医薬組成物
|
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
AU2005238432A1
(en)
*
|
2004-04-14 |
2005-11-10 |
Wyeth |
Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
|
|
AU2005233612A1
(en)
|
2004-04-14 |
2005-10-27 |
Wyeth |
Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
|
|
JP4224115B2
(ja)
*
|
2004-04-14 |
2009-02-12 |
ワイス |
ラパマイシン42−エステル誘導体の位置特異的合成
|
|
CA2562164A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
US7714119B2
(en)
*
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
|
JP5149620B2
(ja)
|
2004-07-23 |
2013-02-20 |
エンドサイト,インコーポレイテッド |
2価リンカーおよびその結合体
|
|
MX2007001676A
(es)
*
|
2004-08-10 |
2007-04-12 |
Wyeth Corp |
Derivados de 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionico y metodos para hacer los mismos.
|
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
BRPI0516308A2
(pt)
*
|
2004-10-04 |
2010-06-15 |
Qlt Usa Inc |
composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
|
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
|
KR20070070184A
(ko)
*
|
2004-10-28 |
2007-07-03 |
와이어쓰 |
자궁근종의 치료에 있어서 mTOR 억제제의 용도
|
|
US20080221660A1
(en)
*
|
2004-10-28 |
2008-09-11 |
Medtronic Vascular, Inc. |
Platelet Gel for Treatment of Aneurysms
|
|
US8021849B2
(en)
*
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
|
ES2364495T3
(es)
|
2005-02-03 |
2011-09-05 |
The General Hospital Corporation |
Método para tratar cáncer resistente a gefitinib.
|
|
CA2595766A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Wyeth |
Cci-779 polymorph and use thereof
|
|
EP1855656A2
(en)
*
|
2005-02-15 |
2007-11-21 |
Wyeth |
Orally bioavailable cci-779 tablet formulations
|
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
|
JP2008531686A
(ja)
*
|
2005-03-02 |
2008-08-14 |
ワイス |
ラパマイシンの精製
|
|
CA2599580A1
(en)
*
|
2005-03-02 |
2006-09-08 |
Wyeth |
Recovery of cci-779 from mother liquors
|
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
|
EP1896018A2
(en)
|
2005-03-11 |
2008-03-12 |
Biotica Technology Limited |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
|
EP1863816B1
(en)
*
|
2005-03-16 |
2014-06-25 |
Endocyte, Inc. |
Synthesis and purification of pteroic acid and conjugates thereof
|
|
WO2006113483A2
(en)
*
|
2005-04-15 |
2006-10-26 |
Schering Corporation |
Methods and compositions for treating or preventing cancer
|
|
US7189582B2
(en)
*
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
WO2007011707A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Polymer coatings containing drug powder of controlled morphology
|
|
WO2007011708A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
AU2006279304A1
(en)
|
2005-08-19 |
2007-02-22 |
Endocyte, Inc. |
Multi-drug ligand conjugates
|
|
EP1933845A2
(en)
|
2005-08-25 |
2008-06-25 |
Medtronic Vascular, Inc. |
Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
|
|
JP5164167B2
(ja)
|
2005-08-30 |
2013-03-13 |
ユニバーシティー オブ マイアミ |
免疫調節性腫瘍壊死因子受容体25(tnfr25)のアゴニスト、アンタゴニスト及び免疫毒素
|
|
WO2007056175A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Wyeth |
41-methoxy isotope labeled rapamycin 42-ester
|
|
JP2009514870A
(ja)
|
2005-11-04 |
2009-04-09 |
ワイス |
mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
|
|
US7622578B2
(en)
*
|
2005-12-07 |
2009-11-24 |
Wyeth |
Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
|
|
BRPI0619592A2
(pt)
*
|
2005-12-07 |
2016-09-06 |
Wyeth Corp |
métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
|
|
AR058282A1
(es)
*
|
2005-12-07 |
2008-01-30 |
Wyeth Corp |
Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
|
|
LT1983984T
(lt)
*
|
2006-02-02 |
2018-06-11 |
Novartis Ag |
Tuberozinės sklerozės gydymas
|
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
|
MX2008011458A
(es)
*
|
2006-03-07 |
2008-09-24 |
Wyeth Corp |
Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos.
|
|
DE102006011507A1
(de)
*
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
|
CA2996768C
(en)
|
2006-04-26 |
2020-12-08 |
Micell Technologies, Inc. |
Coatings containing multiple drugs
|
|
US8241619B2
(en)
|
2006-05-15 |
2012-08-14 |
Medtronic Vascular, Inc. |
Hindered amine nitric oxide donating polymers for coating medical devices
|
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
|
CA2656112A1
(en)
*
|
2006-06-30 |
2008-05-08 |
Hanje Chen |
Bioresponsive polymers
|
|
US20080207671A1
(en)
*
|
2006-07-31 |
2008-08-28 |
The Regents Of The University Of Michigan |
Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
|
|
US20100266590A1
(en)
*
|
2006-08-02 |
2010-10-21 |
Demetri George D |
Combination therapy
|
|
WO2008022256A2
(en)
*
|
2006-08-16 |
2008-02-21 |
Blagosklonny Mikhail V |
Methods and compositions for preventing or treating age-related diseases
|
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
|
EP2083834B1
(en)
|
2006-09-13 |
2017-06-21 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
|
TW200824713A
(en)
*
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Processes for the synthesis of individual isomers of mono-PEG CCI-779
|
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
|
US8067055B2
(en)
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
|
US7691402B2
(en)
*
|
2006-11-06 |
2010-04-06 |
Medtronic Vascular, Inc. |
Block biodegradable copolymers for medical devices
|
|
WO2008058287A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Syndax Pharmaceuticals, Inc. |
COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
|
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
|
WO2008065887A1
(en)
*
|
2006-11-27 |
2008-06-05 |
Terumo Kabushiki Kaisha |
Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
|
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
|
CA2679712C
(en)
|
2007-01-08 |
2016-11-15 |
Micell Technologies, Inc. |
Stents having biodegradable layers
|
|
US7753962B2
(en)
*
|
2007-01-30 |
2010-07-13 |
Medtronic Vascular, Inc. |
Textured medical devices
|
|
US20080188461A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Regents Of The University Of Michigan |
Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
|
|
WO2008101231A2
(en)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
|
US7815927B2
(en)
*
|
2007-03-08 |
2010-10-19 |
Medtronic Vascular, Inc. |
Terpolymers for controlled release of bioactive agents from implantable medical devices
|
|
US7811600B2
(en)
*
|
2007-03-08 |
2010-10-12 |
Medtronic Vascular, Inc. |
Nitric oxide donating medical devices and methods of making same
|
|
CN104127878A
(zh)
|
2007-03-14 |
2014-11-05 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
|
US20080306581A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Medtronic Vascular, Inc. |
Streamlined Stents
|
|
BRPI0812970A2
(pt)
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
|
US8852620B2
(en)
|
2007-07-20 |
2014-10-07 |
Medtronic Vascular, Inc. |
Medical devices comprising polymeric drug delivery systems with drug solubility gradients
|
|
US8273828B2
(en)
*
|
2007-07-24 |
2012-09-25 |
Medtronic Vascular, Inc. |
Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
|
|
US20090043378A1
(en)
*
|
2007-08-10 |
2009-02-12 |
Medtronic Vascular, Inc. |
Biocompatible Polymer System for Extended Drug Release
|
|
US20090076060A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched temsirolimus
|
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
|
CA2701186C
(en)
|
2007-10-05 |
2017-09-19 |
Evonik Canada Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009049426A1
(en)
|
2007-10-19 |
2009-04-23 |
Interface Biologics Inc. |
Self-eliminating coatings
|
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
WO2009089549A1
(en)
*
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Conditional-stop dimerizable caspase transgenic animals
|
|
US20090222088A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Medtronic Vascular, Inc. |
Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
|
|
US20100048524A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
|
US20090232868A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Nitric Oxide Releasing Polymer Composition
|
|
US20090232863A1
(en)
*
|
2008-03-17 |
2009-09-17 |
Medtronic Vascular, Inc. |
Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
|
|
US20090240323A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Medtronic Vascular, Inc. |
Controlled Degradation of Magnesium Stents
|
|
EP2278966B1
(en)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
US20090253733A1
(en)
*
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US20110098241A1
(en)
*
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
|
SG192523A1
(en)
|
2008-04-17 |
2013-08-30 |
Micell Technologies Inc |
Stents having bioabsorbable layers
|
|
US20090269480A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Medtronic Vascular, Inc. |
Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
|
|
US20090299464A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends
|
|
US20090297576A1
(en)
*
|
2008-06-02 |
2009-12-03 |
Medtronic Vascular, Inc. |
Local Delivery of PAR-1 Antagonists to Treat Vascular Complications
|
|
ES2692769T3
(es)
|
2008-06-17 |
2018-12-05 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
|
KR20110020928A
(ko)
|
2008-06-20 |
2011-03-03 |
노파르티스 아게 |
다발성 경화증을 치료하기 위한 소아용 조성물
|
|
EP2313122B1
(en)
|
2008-07-17 |
2019-03-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
US9510856B2
(en)
|
2008-07-17 |
2016-12-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
CN101676291B
(zh)
|
2008-09-18 |
2012-05-09 |
上海海和药物研究开发有限公司 |
一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
|
|
EP2352459A4
(en)
*
|
2008-10-03 |
2013-09-25 |
Elixir Medical Corp |
MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
|
|
US20100092534A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Combination Local Delivery Using a Stent
|
|
US20100092535A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Medtronic Vascular, Inc. |
Nanoporous Drug Delivery System
|
|
EP2365802B1
(en)
|
2008-11-11 |
2017-08-02 |
The Board of Regents,The University of Texas System |
Microcapsules of rapamycin and use for treating cancer
|
|
US20100131001A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Targeted Drug Delivery for Aneurysm Treatment
|
|
US20100131051A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Medtronic Vascular, Inc. |
Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s)
|
|
US20100152832A1
(en)
*
|
2008-12-12 |
2010-06-17 |
Medtronic Vascular, Inc. |
Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
|
|
CA2747558A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
|
CN102256942B
(zh)
|
2008-12-18 |
2013-07-24 |
诺瓦提斯公司 |
1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
|
|
PT2676953T
(pt)
|
2008-12-18 |
2017-06-29 |
Novartis Ag |
Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
|
|
US8158187B2
(en)
*
|
2008-12-19 |
2012-04-17 |
Medtronic Vascular, Inc. |
Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
|
|
US20100198338A1
(en)
*
|
2009-01-30 |
2010-08-05 |
Medtronic Vascular, Inc., A Delaware Corporation |
Hydrogen Sulfide Donating Polymers
|
|
WO2010091306A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
|
US20100227799A1
(en)
*
|
2009-03-09 |
2010-09-09 |
Medtronic Vascular, Inc. |
Simultaneous photodynamic therapy and photo induced polymerization
|
|
WO2010120552A2
(en)
|
2009-04-01 |
2010-10-21 |
Micell Technologies, Inc. |
Coated stents
|
|
US8236341B2
(en)
*
|
2009-04-02 |
2012-08-07 |
Medtronic Vascular, Inc. |
Poly(tetrafluoroethylene) polymer with nitric oxide donating surface
|
|
US20100256728A1
(en)
*
|
2009-04-07 |
2010-10-07 |
Medtronic Vascular, Inc. |
Semi-Permiable Biodegradable Stent Graft and Uses Thereof
|
|
US8709465B2
(en)
*
|
2009-04-13 |
2014-04-29 |
Medtronic Vascular, Inc. |
Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
|
|
CN102481361B
(zh)
|
2009-04-16 |
2014-10-22 |
默沙东公司 |
用于治疗癌症的组合物和方法
|
|
WO2010121187A2
(en)
|
2009-04-17 |
2010-10-21 |
Micell Techologies, Inc. |
Stents having controlled elution
|
|
US8716307B2
(en)
|
2009-05-13 |
2014-05-06 |
The Trustees Of The University Of Pennsylvania |
Combination antineoplastic therapy
|
|
JP2013501057A
(ja)
|
2009-08-03 |
2013-01-10 |
ユニバーシティー・オブ・マイアミ |
制御性t細胞のinvivoにおける増殖
|
|
WO2011051960A2
(en)
|
2009-09-25 |
2011-05-05 |
Cadila Healthcare Limited |
Process for the preparation of rapamycin derivatives
|
|
MX2012004780A
(es)
|
2009-10-23 |
2012-08-23 |
Lilly Co Eli |
Inhibidores de akt.
|
|
CA2777128A1
(en)
|
2009-10-30 |
2011-05-05 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for treating cancer
|
|
US20170079962A1
(en)
|
2009-11-11 |
2017-03-23 |
Rapamycin Holdings, Llc |
Oral Rapamycin Preparation and Use for Stomatitus
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
WO2011072398A1
(en)
|
2009-12-18 |
2011-06-23 |
Interface Biologics, Inc. |
Local delivery of drugs from self assembled coatings
|
|
US8182830B2
(en)
*
|
2010-01-05 |
2012-05-22 |
Medtronic Vascular, Inc. |
Hydrogen sulfide generating polymers
|
|
AU2011210227A1
(en)
*
|
2010-01-28 |
2012-08-30 |
Fresenius Kabi Oncology Ltd. |
Process for the preparation of Temsirolimus and its intermediates
|
|
US11369498B2
(en)
|
2010-02-02 |
2022-06-28 |
MT Acquisition Holdings LLC |
Stent and stent delivery system with improved deliverability
|
|
JP2013521002A
(ja)
|
2010-03-05 |
2013-06-10 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
誘導樹状細胞組成物及びその使用
|
|
CA2797110C
(en)
|
2010-04-22 |
2020-07-21 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
|
EP2563391B1
(en)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
|
WO2011151704A2
(en)
|
2010-06-02 |
2011-12-08 |
Fresenius Kabi Oncology Ltd. |
Stable pharmaceutical compositions of rapamycin esters
|
|
EP2593039B1
(en)
|
2010-07-16 |
2022-11-30 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
EP2601201B1
(en)
*
|
2010-08-04 |
2014-09-24 |
Meril Life Sciences Pvt. Ltd. |
Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
JP2014503499A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく治療に適した被験体の事前選択
|
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
|
EP2455104B1
(en)
|
2010-11-19 |
2013-07-17 |
Universitätsklinikum Freiburg |
Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels
|
|
CN102020662B
(zh)
*
|
2011-01-07 |
2013-02-13 |
天津市炜杰科技有限公司 |
一种驮瑞塞尔制备方法
|
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
|
MX2013011412A
(es)
*
|
2011-04-01 |
2014-04-30 |
Sandoz Ag |
Acilacion regioselectiva de rapamicina en la posicion c-42.
|
|
WO2012143879A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
|
US10117972B2
(en)
|
2011-07-15 |
2018-11-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
CN102424829B
(zh)
*
|
2011-10-26 |
2013-10-16 |
苏州汉酶生物技术有限公司 |
一种酶催化合成坦西莫司的方法
|
|
CA2859089A1
(en)
|
2011-12-16 |
2013-06-20 |
Pfizer Inc. |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
|
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
|
CN102796115B
(zh)
*
|
2012-05-25 |
2015-07-15 |
上海现代制药股份有限公司 |
一种坦西莫司的制备方法
|
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
|
US20150290176A1
(en)
|
2012-10-12 |
2015-10-15 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
|
EP2908818A4
(en)
|
2012-10-16 |
2016-07-13 |
Endocyte Inc |
CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
|
|
US20150258127A1
(en)
|
2012-10-31 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
|
WO2014110258A1
(en)
|
2013-01-09 |
2014-07-17 |
Podack Eckhard R |
Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
AU2014248508B2
(en)
|
2013-03-12 |
2018-11-08 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
|
WO2014186532A1
(en)
|
2013-05-15 |
2014-11-20 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
|
CN103421023B
(zh)
*
|
2013-07-30 |
2015-09-23 |
福建省微生物研究所 |
一种替西罗莫司的合成工艺
|
|
CA2920317A1
(en)
|
2013-08-12 |
2015-02-19 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
CN105899232A
(zh)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
用于增强免疫应答的mTOR抑制剂
|
|
EP2878312A1
(en)
|
2013-12-02 |
2015-06-03 |
Albert-Ludwigs-Universität Freiburg |
Reversible PEGylation of nanocarriers
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
WO2015108912A1
(en)
|
2014-01-16 |
2015-07-23 |
MUSC Foundation for Research and Development |
Targeted nanocarriers for the administration of immunosuppressive agents
|
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2943609A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
CN104086564B
(zh)
*
|
2014-07-30 |
2019-02-05 |
江苏奥赛康药业股份有限公司 |
一种高纯度坦罗莫司的制备方法
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
EP2997977A1
(en)
|
2014-09-19 |
2016-03-23 |
Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe |
Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
US10377818B2
(en)
|
2015-01-30 |
2019-08-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of treating glioma
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
HK1245095A1
(zh)
|
2015-05-20 |
2018-08-24 |
Novartis Ag |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
|
IL258574B2
(en)
|
2015-11-11 |
2025-01-01 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and their uses
|
|
US10765665B2
(en)
|
2015-11-24 |
2020-09-08 |
Melin Jeffrey |
Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
|
|
WO2020047527A2
(en)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
|
|
EP3442540A4
(en)
|
2016-04-14 |
2019-12-18 |
Spinnaker Biosciences Inc. |
POROUS SILICON MATERIALS WITH A METAL SILICATE FOR DELIVERING THERAPEUTIC ACTIVE SUBSTANCES
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
WO2018057788A1
(en)
|
2016-09-22 |
2018-03-29 |
Mercator Medsystems, Inc. |
Treatment of restenosis using temsirolimus
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
JP2020507632A
(ja)
|
2017-02-10 |
2020-03-12 |
マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. |
ラパマイシン類似体
|
|
AU2018226884B2
(en)
|
2017-03-03 |
2024-11-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3848065B1
(en)
|
2017-05-15 |
2023-07-26 |
C. R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
|
CN108948045A
(zh)
*
|
2017-05-20 |
2018-12-07 |
鲁南制药集团股份有限公司 |
一种替西罗莫司的制备方法
|
|
AU2018272061A1
(en)
|
2017-05-26 |
2020-01-02 |
Mercator Medsystems, Inc. |
Combination therapy for treatment of restenosis
|
|
WO2019002168A1
(en)
|
2017-06-26 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
|
|
EP3652306A1
(en)
|
2017-07-13 |
2020-05-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
|
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
|
CN212631328U
(zh)
|
2018-03-14 |
2021-03-02 |
墨卡托医疗系统公司 |
用于局部药物递送的医疗器械
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
|
IL300091A
(en)
|
2018-05-01 |
2023-03-01 |
Revolution Medicines Inc |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3796948A4
(en)
|
2018-05-22 |
2022-03-02 |
Interface Biologics Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF MEDICATIONS TO A VESSEL WALL
|
|
CN113164557A
(zh)
|
2018-07-23 |
2021-07-23 |
因柯利尔疗法公司 |
治疗神经性病症的方法
|
|
JP2022510573A
(ja)
|
2018-07-23 |
2022-01-27 |
エンクリアー セラピーズ, インク. |
神経障害の治療方法
|
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
|
CN113164576A
(zh)
|
2018-10-05 |
2021-07-23 |
圣安娜儿童癌症研究中心 |
嵌合抗原受体(car)组
|
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
CA3112310C
(en)
|
2018-10-05 |
2025-05-06 |
Universitat Fur Bodenkultur Wien |
CHIMERIC ANTIGEN RECEPTOR GROUP (CAR)
|
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3880266B1
(en)
|
2018-11-14 |
2025-05-07 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
MX2021007247A
(es)
|
2018-12-18 |
2021-07-15 |
Novartis Ag |
Derivados de rapamicina.
|
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
|
WO2020163594A1
(en)
|
2019-02-07 |
2020-08-13 |
The Regents Of The University Of California |
Immunophilin binding agents and uses thereof
|
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
JP2022526671A
(ja)
|
2019-04-11 |
2022-05-25 |
エンクリアー セラピーズ, インク. |
脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
|
|
MX2022000279A
(es)
|
2019-07-07 |
2022-02-03 |
Olema Pharmaceuticals Inc |
Regimenes de antagonistas del receptor de estrogeno.
|
|
CN113372359A
(zh)
*
|
2020-03-10 |
2021-09-10 |
鲁南制药集团股份有限公司 |
一种坦西莫司的制备方法
|
|
JP2023543868A
(ja)
|
2020-09-29 |
2023-10-18 |
エンクリアー セラピーズ, インク. |
くも膜下液管理方法およびシステム
|
|
EP4240356A1
(en)
|
2020-11-03 |
2023-09-13 |
RDiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
|
AU2023275778A1
(en)
|
2022-05-25 |
2024-12-12 |
Revolution Medicines, Inc. |
Methods of treating cancer with an mtor inhibitor
|
|
JP2025521677A
(ja)
|
2022-07-06 |
2025-07-10 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
増殖性糸球体腎炎を処置するための方法
|
|
US20260060969A1
(en)
|
2022-08-04 |
2026-03-05 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
|
EP4615431A1
(en)
|
2022-11-11 |
2025-09-17 |
Astrazeneca AB |
Combination therapies for the treatment of cancer
|